At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 378 enrolled
Drug / intervention
guaifenesin (Mucinex) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days
In Brief
A Phase 2 clinical trial evaluating guaifenesin (Mucinex) and placebo for Common Cold. Completed, enrolled 378 participants across 1 site.
Detailed Summary
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedJan 2010
Primary CompletionMar 2010
TodayJul 2026
First PostedJan 11, 2010
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.5 years ago
Interventions
guaifenesin (Mucinex)drug
bid 7 days
placebodrug
bid 7 days